BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ • Healthcare

$8.43

+$0.26 (+3.3%)

Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$8.15

Day Range$8.12 - $8.45

Avg. Volume (3M)3.7M

Market Cap$2.1B

52 Week Range

$6$11.22

Next EarningsIn 47 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$218.2M100%

Gross Profitminus cost of goods$214.4M98%

Operating Incomeminus R&D and overhead$98.4M45%

Net Incomeminus taxes and the rest$78.3M36%

In plain terms: out of every $100 in revenue, BioCryst Pharmaceuticals, Inc. keeps $36 as net profit.

Fundamentals & Financials

Revenue (TTM)

$940.6M

Net Income (TTM)

-$384.6M

EPS (TTM)

-$1.44

ROA (TTM)

-68.96%

Current Ratio

2.32

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-33.3%Q3 2025$0.02

-14.3%Q4 2025$0.06

+1500.0%Q1 2026$1.12

-5066.7%Q2 2026-$2.98

+94.6%Q3 2026$0.3

Nov 2

in 47 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +94.6%

BioCryst Pharmaceuticals’ revenue topped consensus in the second fiscal quarter of 2026, with results reported August 5, 2026, as revenue rose 33.6% to about $218.2 million, up from $163.4 million a year ago. On the consensus yardstick, revenue of $218.2 million topped the $183.3 million estimate (+19.1%), pointing to a materially higher quarter than analysts were modeling. Profitability was high on a margin basis, with gross margin at roughly 98% and operating margin around 45%, alongside operating income of about $98.5 million; gross profit came in at roughly $214.4 million. The company also generated operating cash flow of about $104.3 million during the quarter. For the next period, consensus calls for EPS of $0.10 on revenue of $165.4 million.

View full earnings history

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. develops and commercializes biotechnology medicines for rare and infectious diseases, with $874.8 million in revenue in FY2025. The NASDAQ-listed BCRX company centers on small-molecule therapeutics, particularly orally administered drug candidates, and sells approved products for hereditary angioedema and influenza.

Name

BioCryst Pharmaceuticals, Inc.

CEO

Charles K. Gayer

Website

www.biocryst.com

Industry

Healthcare

Year Founded

1986

Employees

435

Today's Snapshot

AI-generated

BCRX closed 3.3% higher at 8.43, while its sector was flat.

Trading Volume

Above 10d avg 5.0M

5.1M

vs S&P 500 Today

Strong Outperformance

+3.89%

Updated: September 16, 2026 at 20:23 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

BCRX trades about 8.43 and displays a clear bearish tilt despite a few short‑term oversold signals. Momentum measures such as MACD and CCI are negative and price is beneath most short‑ and medium‑term averages, with the 200‑day roughly overhead, signaling extended weakness. ADX is modestly higher than peers but not strong, volatility is elevated for the share price with ATR near 4.8%, and OBV is markedly negative, consistent with distribution. The classic pivot sits slightly below the market but has not offset broader selling pressure. Technical takeaway: Strong Sell.

All signals